Objective To investigate the serum level of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific RBD IgG antibody (SARS-CoV-2 IgG antibody for short) in children with SARS-CoV-2 Omicron variant infection during the recovery stage, as well as the protective effect of SARS-CoV-2 vaccination against Omicron infection. Methods A retrospective analysis was performed on 110 children who were diagnosed with coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 Omicron variant infection in Tianjin of China from January 8 to February 7, 2022. According to the status of vaccination before diagnosis, they were divided into a booster vaccination (3 doses) group with 2 children, a complete vaccination (2 doses) group with 90 children, an incomplete vaccination (1 dose) group with 5 children, and a non-vaccination group with 13 children. The clinical data and IgG level were compared among the 4 groups. Results The complete vaccination group had a significantly higher age than the non-vaccination group at diagnosis (P<0.05), and there was a significant difference in the route of transmission between the two groups (P<0.05). There were no significant differences among the four groups in sex, clinical classification, and re-positive rate of SARS-CoV-2 nucleic acid detection (P>0.05). All 97 children were vaccinated with inactivated vaccine, among whom 85 children (88%) were vaccinated with BBIBP-CorV Sinopharm vaccine (Beijing Institute of Biological Products, Beijing, China). At 1 month after diagnosis, the booster vaccination group and the complete vaccination group had a significantly higher level of SARS-CoV-2 IgG antibody than the non-vaccination group (P<0.05), and at 2 months after diagnosis, the complete vaccination group had a significantly higher level of SARS-CoV-2 IgG antibody than the non-vaccination group (P<0.05). For the complete vaccination group, the level of SARS-CoV-2 IgG antibody at 2 months after diagnosis was significantly lower than that at 1 month after diagnosis (P<0.05). Conclusions Vaccination with inactivated SARS-CoV-2 vaccine has a protective effect against Omicron infection in children. For children vaccinated with 2 doses of the vaccine who experience Omicron infection, there may be a slight reduction in the level of SARS-CoV-2 IgG antibody at 2 months after diagnosis. Citation:Chinese Journal of Contemporary Pediatrics, 2022, 24(7): 736-741
Key words
Coronavirus disease 2019 /
Omicron /
IgG /
Vaccination /
Recovery stage /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern[J]. Lancet, 2020, 395(10223): 470-473. PMID: 31986257. PMCID: PMC7135038. DOI: 10.1016/S0140-6736(20)30185-9.
2 Callaway E. Heavily mutated Omicron variant puts scientists on alert[J]. Nature, 2021, 600(7887): 21. PMID: 34824381. DOI: 10.1038/d41586-021-03552-w.
3 Yang Y, Du L. SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies[J]. Signal Transduct Target Ther, 2021, 6(1): 95. PMID: 33637679. PMCID: PMC7908000. DOI: 10.1038/s41392-021-00523-5.
4 Muruato AE, Fontes-Garfias CR, Ren P, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation[J]. Nat Commun, 2020, 11(1): 4059. PMID: 32792628. PMCID: PMC7426916. DOI: 10.1038/s41467-020-17892-0.
5 Salazar E, Kuchipudi SV, Christensen PA, et al. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization[J]. J Clin Invest, 2020, 130(12): 6728-6738. PMID: 32910806. PMCID: PMC7685744. DOI: 10.1172/JCI141206.
6 Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine[J]. Lancet, 2021, 397(10280): 1178-1181. PMID: 33640037. PMCID: PMC7993933. DOI: 10.1016/S0140-6736(21)00502-X.
7 Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients[J]. Sci Immunol, 2020, 5(52): eabe0367. PMID: 33033172. PMCID: PMC7857394. DOI: 10.1126/sciimmunol.abe0367.
8 中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第八版)[J]. 中华临床感染病杂志, 2020, 13(5): 321-328. DOI: 10.3760/cma.j.issn.1674-2397.2020.05.001.
9 郑跃杰, 王晓川, 冯录召, 等. 儿童新型冠状病毒疫苗接种专家共识[J]. 中华实用儿科临床杂志, 2021, 36(18): 1361-1367. DOI: 10.3760/cma.j.cn101070-20210902-01057.
10 中华人民共和国国家卫生健康委员会疾病预防控制局. 新冠病毒疫苗接种情况[EB/OL]. (2022-04-27)[2022-05-06]. http://www.nhc.gov.cn/jkj/s7915/202204/c081d58377d04416879df542507b3717.shtml.
11 郑文彬, 汤建桥, 丘燕燕, 等. 武汉市儿童2019新型冠状病毒感染146例的临床特征分析[J]. 中华传染病杂志, 2020, 38(10): 626-630. DOI: 10.3760/cma.j.cn311365-20200311-00272.
12 Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study[J]. Lancet, 2022, 399(10332): 1303-1312. PMID: 35305296. PMCID: PMC8926413. DOI: 10.1016/S0140-6736(22)00462-7.
13 Dorabawila V, Hoefer D, Bauer UE, et al. Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the emergence of the Omicron variant[J]. medRxiv[Preprint]. (2022-02-28) [2022-03-25]. DOI: 10.1101/2022.02.25.22271454.
14 Chia WN, Tan CW, Foo R, et al. Serological differentiation between COVID-19 and SARS infections[J]. Emerg Microbes Infect, 2020, 9(1): 1497-1505. PMID: 32529906. PMCID: PMC7473126. DOI: 10.1080/22221751.2020.1780951.
15 Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection[J]. Nature, 2021, 595(7867): 426-431. PMID: 34126625. PMCID: PMC8277577. DOI: 10.1038/s41586-021-03696-9.
16 Seaman MS, Siedner MJ, Boucau J, et al. Vaccine breakthrough infection with the SARS-CoV-2 Delta or Omicron (BA.1) variant leads to distinct profiles of neutralizing antibody responses[J]. medRxiv[Preprint]. (2022-03-03) [2022-04-16]. PMID: 35262094. PMCID: PMC8902886. DOI: 10.1101/2022.03.02.22271731.
17 Wang K, Cao Y, Zhou Y, et al. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2[J]. medRxiv[Preprint]. (2021-09-05) [2022-03-05]. DOI: 10.1101/2021.09.02.21261735.
18 Sughayer MA, Souan L, Abu Alhowr MM, et al. Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: implications for vaccine strategies[J]. Vaccine, 2022, 40(20): 2841-2847. PMID: 35397946. PMCID: PMC8971065. DOI: 10.1016/j.vaccine.2022.03.069.
19 Brewster RCL, Parsons C, Laird-Gion J, et al. COVID-19-associated croup in children[J]. Pediatrics, 2022, 149(6): e2022056492. PMID: 35257175. DOI: 10.1542/peds.2022-056492.
20 焦富勇, 马蕾. 加强儿童奥密克戎感染的防治[J]. 中国当代儿科杂志, 2022, 24(4): 345-349. PMID: 35527405. PMCID: PMC9044981. DOI: 10.7499/j.issn.1008-8830.2201001.
PDF(514 KB)
